MSNP-Based Delivery System Development

Inquiry

Mesoporous silica nanoparticles (MSNPs) are nanoscale particles composed of silica (silicon dioxide) with a highly ordered porous structure. They typically have a spherical shape and can range in size from several nanometers to hundreds of nanometers. At Alfa Cytology, we have established a proprietary MSNs platform to help you develop novel drug delivery system for bladder cancer.

Introduction to MSNP-Based Delivery System

The excellent biocompatibility, high stability, rigid backbone, good pore structure, tunable surface chemistry and controlled release of drugs of mesoporous silica nanoparticles (MSNPs) determine them to be excellent drug carriers. Their unique properties make them attractive candidates for targeted drug delivery, imaging, and therapeutic monitoring in bladder cancer. Therefore, MSNPs have shown great potential in the field of bladder cancer therapy.

Fig 1. Schematic illustrating the critical advances and specific attributes of engineered MSNs. (Kankala R. K. et al. 2020)

Here are some key advantages of MSNs for bladder cancer:

Targeted Drug Delivery
Enhanced Drug Loading Capacity
Preclinical Imaging

Controlled Drug Release
Combination Therapies
Biocompatibility and Stability

Our Services

Alfa Cytology, a leading company in preclinical contract research organization (CRO) services, Alfa Cytology is working on the development of a mesoporous silica nanoparticle (MSNP)-based drug delivery system for bladder cancer. To further enhance the efficacy and specificity of the MSNP-based drug delivery system, we focus on the following areas:

Development of Targeting MSNP-Based DDS		Development of Stimulus Responsive MSNP-Based DDS
Passive Targeting MSNPs	Active Targeting MSNPs transferrin (Tf) Epidermal growth factor (EGF) Hyaluronic acid (HA)…	Temperature-triggered MSNPs Ultrasound-triggered MSNPs Light-triggered MSNPs Magnetically-responsive MSNPs	pH-responsive MSNPs Redox potential-responsive MSNPs Enzyme-responsive MSNPs

By integrating these targeting and stimulus-responsive strategies, we can develop a sophisticated MSN-based drug delivery system that offers enhanced specificity, controlled drug release, and improved therapeutic outcomes for bladder cancer.

Our Solutions Will Help You Achieve the Goals.

Enhanced Targeting of Bladder Cancer Cells
Controlled and Triggered Drug Release for Bladder Cancer
Preclinical Therapeutic Monitoring and Imaging

Contact Us

Alfa Cytology is your trusted partner in the development and translation of MSN-based drug delivery systems for bladder cancer treatment. With our expertise in formulation development, evaluation, and regulatory support, we are well-equipped to assist you in harnessing the advantages of MSNs in enhancing therapeutic outcomes. Contact us today to explore the possibilities of this innovative approach in cancer therapy.

Reference

Vallet-Regí M., Colilla M., and et al. Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights. Molecules. 2018, 23(1): 47.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.